BioXcel Therapeutics, Inc. announced promising results for BXCL501, the Company s proprietary,ally dissolving film of dexmedetomidine under investigation for the treatment of agitation, in Part 1 of. | May 26, 2023
BioXcel Therapeutics (BTAI) Announces Promising Topline Results from Part 1 of SERENITY III Trial of BXCL501 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BXCL501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo .